Aubrey Rankin, President, Innovation & Technology at Revance Therapeutics, Inc. (RVNC), sold 2 shares at $28.28 ($57) on 2021-04-05, disclosed to the SEC on 2021-04-06.
Scheduled sale ($57) by President, Innovation & Technology under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RVNC | SELL | 2021-07-30 | $1.6M | — | Filing → |
| RVNC | SELL | 2021-07-28 | $3.3M | — | Filing → |
| RVNC | SELL | 2021-03-05 | $1.7M | — | Filing → |